We are live on
!
Find out more
UOC
UBS O'Connor Portfolio holdings
AUM
$3.76B
1-Year Est. Return
62.41%
This Fund
S&P 500
This Quarter
Est. Return
+8.61%
1 Year Est. Return
+62.41%
3 Year Est. Return
+179.84%
5 Year Est. Return
+371.69%
10 Year Est. Return
+1,534.25%
AUM
$5.42B
AUM Growth
-$3.38B
(-38%)
Cap. Flow
-$3.75B
Cap. Flow
% of AUM
-69.25%
Top 10 Holdings %
Top 10 Hldgs %
40.63%
Holding
1,042
New
84
Increased
109
Reduced
414
Closed
284
Avg Time Held Equity + Options
3.7
quarters
Top 10 Avg Time Held Equity + Options
0.5
quarters
Top 20 Avg Time Held Equity + Options
0.8
quarters
Avg Time Held Equity only
3.7
quarters
Top 10 Avg Time Held Equity only
0.5
quarters
Top 20 Avg Time Held Equity only
0.8
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$184M |
| 2 |
STOR
STORE Capital Corporation
STOR
|
+$172M |
| 3 |
First Horizon
FHN
|
+$107M |
| 4 |
COUP
Coupa Software Incorporated
COUP
|
+$96.9M |
| 5 |
AAWW
Atlas Air Worldwide Holdings, Inc.
AAWW
|
+$64.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$572M |
| 2 |
ZEN
ZENDESK INC
ZEN
|
+$456M |
| 3 |
AVLR
Avalara, Inc.
AVLR
|
+$373M |
| 4 |
SWCH
Switch, Inc. Class A Common Stock
SWCH
|
+$271M |
| 5 |
Rogers Corp
ROG
|
+$219M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 25.7% |
| 2 | Technology | 18.31% |
| 3 | Healthcare | 15.11% |
| 4 | Miscellaneous | 11.75% |
| 5 | Real Estate | 10.91% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
426
Aclaris Therapeutics
ACRS
$530M
| $2.12M | 0.04% |
134,693
+21,267
| +19% | +$342K |
2022 Q1
3 quarters
|
|
427
AtriCure
ATRC
$2.91B
| $2.12M | 0.04% |
47,700
+35,400
| +288% | +$1.48M |
2022 Q3
1 quarter
|
|
428
AstraZeneca
AZN
$246B
| $2.1M | 0.04% |
15,524
-32,691
| -68% | -$4.1M |
2022 Q1
3 quarters
|
|
429
IDEAYA Biosciences
IDYA
$3.48B
| $2.1M | 0.04% |
115,570
+35,458
| +44% | +$597K |
2022 Q3
1 quarter
|
|
|
MRTX
430
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $2.08M | 0.04% |
+46,000
| New | +$2.98M |
2022 Q4
0 quarters
|
|
431
DELISTED
Crinetics Pharmaceuticals
CRNX
| $2.06M | 0.04% |
112,421
+21,961
| +24% | +$387K |
2022 Q1
3 quarters
|
|
432
DELISTED
Aetherium Acquisition Corp
GMFI
| $2.05M | 0.04% |
201,057
-1,967
| -1% | -$19.8K |
2022 Q1
3 quarters
|
|
433
Pentair
PNR
$8.35B
| $2.04M | 0.04% |
+45,468
| New | +$1.98M |
2022 Q4
0 quarters
|
|
434
Zymeworks
ZYME
$1.82B
| $2.04M | 0.04% |
259,268
+44,268
| +21% | +$311K |
2022 Q2
2 quarters
|
|
435
Oric Pharmaceuticals
ORIC
$1.22B
| $2.04M | 0.04% |
345,435
+2,433
| +0.7% | +$8.21K |
2022 Q2
2 quarters
|
|
436
Glaukos
GKOS
$9.91B
| $2.02M | 0.04% |
46,227
+13,535
| +41% | +$668K |
2022 Q1
3 quarters
|
|
437
Ladder Capital
LADR
$1.11B
| $2.02M | 0.04% |
200,655
+63,333
| +46% | +$656K |
2022 Q2
2 quarters
|
|
438
First Solar
FSLR
$19.3B
| $2M | 0.04% |
13,322
-49,098
| -79% | -$7.27M |
2022 Q3
1 quarter
|
|
439
Biogen
BIIB
$33.9B
| $1.96M | 0.04% |
7,065
+1,115
| +19% | +$315K |
2022 Q3
1 quarter
|
|
440
Viridian Therapeutics
VRDN
$2.07B
| $1.94M | 0.04% |
66,460
-15,410
| -19% | -$355K |
2022 Q1
3 quarters
|
|
441
DELISTED
Lionheart III Corp Class A Common Stock
LION
| $1.94M | 0.04% |
189,048
-1,850
| -1% | -$18.7K |
2021 Q4
4 quarters
|
|
|
NGC
442
DELISTED
Northern Genesis Acquisition Corp. III
NGC
| $1.93M | 0.04% |
192,205
-1,881
| -1% | -$18.7K |
2021 Q2
6 quarters
|
|
|
FRBN
443
DELISTED
Forbion European Acquisition Corp. Class A Ordinary Shares
FRBN
| $1.92M | 0.04% |
185,349
-1,814
| -1% | -$18.5K |
2022 Q2
2 quarters
|
|
|
SWSS
444
DELISTED
Clean Energy Special Situations Corp. Common stock
SWSS
| $1.92M | 0.04% |
378,096
-3,700
| -1% | -$18.6K |
2021 Q4
4 quarters
|
|
445
DELISTED
Integrated Wellness Acquisition Corp
WEL
| $1.91M | 0.04% |
185,349
-1,814
| -1% | -$18.5K |
2022 Q1
3 quarters
|
|
446
DELISTED
HCM Acquisition Corp Class A Ordinary Shares
HCMA
| $1.9M | 0.04% |
185,349
-1,814
| -1% | -$18.5K |
2022 Q1
3 quarters
|
|
|
CPTK
447
DELISTED
Crown PropTech Acquisitions
CPTK
| $1.89M | 0.03% |
187,129
-1,839
| -1% | -$18.4K |
2021 Q2
6 quarters
|
|
448
Lamar Advertising Co
LAMR
$14.9B
| $1.89M | 0.03% |
+20,003
| New | +$1.85M |
2022 Q4
0 quarters
|
|
449
flyExclusive
FLYX
$70.4M
| $1.88M | 0.03% |
188,312
-1,843
| -1% | -$18.2K |
2021 Q3
5 quarters
|
|
|
ARYE
450
DELISTED
ARYA Sciences Acquisition Corp V Class A Ordinary Shares
ARYE
| $1.86M | 0.03% |
185,349
-1,814
| -1% | -$18K |
2022 Q1
3 quarters
|
|
Similar funds
FNBT
ACI
RC
A
CGL
CB
JCM
MPM
UBS O'Connor's Q4 2022 Portfolio in Review
As of Q4 2022, UBS O'Connor held 1,042 positions worth $5.42B, down 38% from $8.8B the previous quarter. Its ten largest holdings account for 41% of the portfolio.
UBS O'Connor withdrew a net $3.75B in Q4 2022, closing 284 positions and reducing 414 holdings. Its most notable exit was Biohaven Pharmaceutical Holding Company Ltd., an estimated $572M position sold in full.
By sector, the portfolio is most concentrated in Financials at 26% of assets, up from 20% a quarter earlier, followed by Technology and Healthcare.
Against the trend, UBS O'Connor opened a new position in Coupa Software Incorporated worth $128M.
- UBS O'Connor's largest Q4 2022 buy was Coupa Software Incorporated: 1,619,333 shares worth $128M.
- UBS O'Connor added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2022, an estimated $184M increase.
- UBS O'Connor's biggest Q4 2022 reduction was Rogers Corp, cutting an estimated $219M.
- UBS O'Connor fully exited Biohaven Pharmaceutical Holding Company Ltd. in Q4 2022, selling an estimated $572M.
- UBS O'Connor's ten largest holdings make up 41% of its $5.42B portfolio in Q4 2022.
- UBS O'Connor opened 84 new positions and closed 284 in Q4 2022.
- UBS O'Connor's portfolio value fell 38% quarter-over-quarter to $5.42B.
Based on UBS O'Connor's 13F filing for Q4 2022, filed 14 Feb 2023.